Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion
In the absence of an iron chelating agent, patients with beta-thalassemia on regular transfusions present complications of transfusion-related iron overload. Without iron chelation therapy, heart disease is the major cause of death; however, hepatic and endocrine complications also occur. Currently...
Main Authors: | Monica Pinheiro de Almeida Verissimo, Sandra Regina Loggetto, Antonio Fabron Junior, Giorgio Roberto Baldanzi, Nelson Hamerschlak, Juliano Lara Fernandes, Aderson da Silva Araujo, Clarisse Lopes de Castro Lobo, Kleber Yotsumoto Fertrin, Vasilios Antonios Berdoukas, Renzo Galanello |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2013-01-01
|
Series: | Revista Brasileira de Hematologia e Hemoterapia |
Subjects: | |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842013000600428&lng=en&tlng=en |
Similar Items
-
Iron Chelator Drugs in Transfusion Dependent Thalassemia: a Review
by: M Hashemieh
Published: (2020-08-01) -
Adherence to Iron Chelation Therapy and Its Determinants
by: Sukhmani Sidhu, et al.
Published: (2021-01-01) -
Development of Thalassemia Medication Questionnaire (TMQ): An Instrument for Measuring Major Thalassemia Patients’ Knowledge and Practice Regarding their Medications
by: Azita Azarkeivan, et al.
Published: (2022-12-01) -
Safety and Efficacy of the New Combination Iron Chelation Regimens in Patients with Transfusion-Dependent Thalassemia and Severe Iron Overload
by: Raffaella Origa, et al.
Published: (2022-04-01) -
Use of Deferasirox Film-Coated Tablets in Pediatric Patients with Transfusion Dependent Thalassemia: A Single Center Experience
by: Alkistis Adramerina, et al.
Published: (2022-02-01)